Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Stock Information for Applied Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Applied Therapeutics Inc.

Applied Therapeutics Announces Key Leadership Appointments
Applied Therapeutics Reports First Quarter 2025 Financial Results
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
NET Power Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 17, 2025 Deadline to file Lead Plaintiff Motion
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
APLT DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - APLT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.